Charles River defines patient-derived tumor grafts as explants established as models at low passage numbers (average of 6 passes removed from patient). They have not been grown in plastic or propagated as cell cultures.
Establishing xenograft tumor models from patient-derived tumor tissue (PDTT) at low passage is believed to conserve original tumor characteristics such as heterogeneous histology, clinical biomolecular signature, malignant phenotypes and genotypes, tumor architecture and tumor vasculature. Based on this prevalent hypothesis, patient-derived tumor grafts are believed to offer relevant predictive insights into clinical outcomes when evaluating the efficacy of novel cancer therapies.
By leveraging the wealth of information that we have on each tumor model, we can help you with your study and provide suggested PDX models to test.
Tell Us More About Your Target/Study »
We currently have more than 400 fully characterized proprietary patient-derived xenografts (PDXs) in our portfolio, which represent all major histotypes and tumors, and provide extensive background and characterization.
Our PDX portfolio includes:
Subcutaneous, orthotopic and disseminated models
Extensive molecular and pharmacological characterization, and complete records on patients‘ pretreatment
Integrated approach using the same PDX models and/or the corresponding cell line
2D/3D screening assays and subsequent in vivo studies
Identification of biomarkers, which predicts tumor sensitivity of compounds
Constant addition of new models, which are continuously established through international collaborations with major hospitals and universities
To learn more about our offerings, including molecular information, visit our PDX Compendium.